Basics Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment. IPO Date: March 16, 2004 Sector: Healthcare Industry: Biotech Market Cap: $8.76B Activated in VL: True Average Daily Range Avg Daily Range: $0.38 | 2.15% Avg Daily Range (30 D): $0.73 | 1.11% Avg Daily Range (90 D): $0.89 | 1.52% Institutional Daily Volume Avg Daily Volume: .96M Avg Daily Volume (30 D): 1.72M Avg Daily Volume (90 D): 1.88M Trade Size Avg Trade Size (Sh.): 107 Avg Trade Size (Sh.) (30 D): 56 Avg Trade Size (Sh.) (90 D): 60 Institutional Trades Total Inst.Trades: 9,311 Avg Inst. Trade: $2.82M Avg Inst. Trade (30 D): $4.47M Avg Inst. Trade (90 D): $4.55M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $5.43M Avg Closing Trade (30 D): $17.43M Avg Closing Trade (90 D): $21.15M Avg Closing Volume: 157.52K     News Sep 6, 2025 @ 7:10 AM RYBREVANT®▼ (amivantamab) plus LAZCLUZEÂ... Source: Johnson & Johnson Aug 26, 2025 @ 8:00 PM Acumen Pharmaceuticals to Participate in Upcoming ... Source: Acumen Pharmaceuticals Aug 6, 2025 @ 2:26 AM Halozyme (HALO) Q2 EPS Jumps 69% Source: Jesterai Aug 5, 2025 @ 8:00 PM Acumen Pharmaceuticals to Report Second Quarter 20... Source: Acumen Pharmaceuticals Apr 10, 2025 @ 9:47 PM argenx Announces FDA Approval of VYVGART Hytrulo P... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $4.48 $1.36 $.96 Diluted EPS $4.37 $1.33 $.93 Revenue $ 1.18B $ 325.72M $ 264.86M Gross Profit $ 992.43M $ 279.36M $ 216.46M Net Income / Loss $ 557.28M $ 165.16M $ 118.1M Operating Income / Loss $ 682.67M $ 202.44M $ 141.54M Cost of Revenue $ 186.24M $ 46.36M $ 48.4M Net Cash Flow $ -126M $ -114.47M $ 60.48M PE Ratio 17.15